若不治疗耐多药结核病的危险。
The risk of leaving multidrug-resistant tuberculosis untreated.
应对耐多药结核病方面取得的进展
但这些病例中有多少是耐多药结核病？
预防和控制耐多药结核病和广泛耐药结核病。
Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
问：你什么时候开始介入耐多药结核病问题的？
因此，出现各种耐多药结核病管理不善的情况。
As a result all kinds of poor management of MDR-TB are happening.
什么是耐多药结核和广泛耐药结核的医学定义？
这就是耐多药结核病的出现和传播所带来的前景。
This is the perspective created by the emergence and spread of drug-resistant tuberculosis.
在2006年，估计有50万例耐多药结核病例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2006.
2007年，耐多药结核病例估计数为50万例。
There were an estimated 0.5 million cases of multidrug-resistant TB (MDR-TB) in 2007.
问：你对与耐多药结核病作斗争的前途有什么看法？
这不仅意味着拯救耐多药结核病人，也拯救所有的人。
That means not only saving the people with MDR-TB but also the general population.
在研究的544名患者中，有221人患有耐多药结核。
问：哈萨克斯坦与耐多药结核病作斗争的核心内容是什么？
Q: What's the most important part of Kazakhstan's fight against drug-resistant TB?
这相当于痰涂阳性的耐多药结核病例全球估计总数的1%。
This is equivalent to 1% of the estimated global total of smear-positive cases of MDR-TB.
估计全世界将近50%的耐多药结核病例发生在中国和印度。
Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India.
结核病规划在减少耐多药结核病发病率方面面临着巨大挑战。
Tuberculosis programmes face tremendous challenges in reducing MDR-TB rates.
菲律宾像世界任何国家一样，长期以来设法控制耐多药结核病。
The Philippines has tried to control multidrug-resistant TB (MDR -TB ) for nearly as long as any country in the world.
这仅相当于痰涂阳性耐多药结核病例全球估计总数的8.5%。
This was 8.5% of the estimated global total of smear-positive cases of MDR-TB.
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
到2008年底，耐多药结核病项目总共治疗了1316例病人。
By the end of 2008, the MDR-TB project had treated 1316 patients in all.
结核病控制在稳步取得进步，但耐多药结核病却达到了历史较高水平。
Progress in tuberculosis control remains steady but multi-drug resistant TB has reached historic levels.
形成耐多药结核或广泛耐药结核的第二个途径是患者自身的结核产生耐药性。
A second way of developing MDR-TB or XDR-TB is when a patient's own TB develops resistance.
用二线药物治疗耐多药结核所需时间更长，更加昂贵，并且产生更多副作用。
MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects.
在治疗耐多药结核的二线药物被滥用的任何地方，存在着广泛耐药结核的可能性。
Wherever second-line drugs to treat MDR-TB are being misused, the possibility of XDR-TB exists.
耐多药结核描述至少对两种主要一线抗结核药物-异烟肼和利福平具耐药性的结核菌株。
MDR-TB (Multidrug Resistant TB) describes strains of tuberculosis that are resistant to at least the two main first-line TB drugs - isoniazid and rifampicin.
所有接受此项援助的国家均已符合世卫组织的管理耐多药结核技术标准，并已经具备治疗规划。
All the countries receiving this assistance have met WHO's technical standards for managing MDR-TB and already have treatment programmes in place.
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
在耐多药结核发生率最高之一的国家拉脱维亚，19%的耐多药结核病例符合广泛耐药结核的标准。
In Latvia, a country with one of the highest rates of MDR-TB, 19% of MDR-TB cases met the XDR-TB criteria.
在耐多药结核发生率最高之一的国家拉脱维亚，19%的耐多药结核病例符合广泛耐药结核的标准。
In Latvia, a country with one of the highest rates of MDR-TB, 19% of MDR-TB cases met the XDR-TB criteria.
应用推荐